Apixaban Versus Warfarin for Left Ventricular Thrombus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 218 participants.

Also called NCT07709780

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 218 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07709780
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07709780. Randomized; no masking; primary purpose treatment. Start 2026-06-22 (anticipated); primary completion 2028-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban Versus Warfarin for Left Ventricular Thrombus
Acronym
APEX
Condition
Left Ventricular Thrombus
Intervention (Drug)
Apixaban
Intervention (Drug)
Warfarin
Lead sponsor
University of Arizona (class: other)

Record details

Record id
cardio:ct-nct07709780
Content hash
9ec7e029943ef43ab79de008886d93b63cdab385b27b11345aefb03e6b6194d7